Paya Carlos V 4
4 · COLLEGIUM PHARMACEUTICAL, INC · Filed May 18, 2026
Research Summary
AI-generated summary of this filing
Collegium (COLL) Director Carlos V. Paya Receives RSU Award
What Happened
Carlos V. Paya, a director of Collegium Pharmaceutical, Inc. (COLL), was granted 8,741 restricted stock units (RSUs) on May 14, 2026. The award is reported at $0.00 on the Form 4 because it is a contingent equity grant (transaction code A). Each RSU represents a contingent right to one share of common stock and will convert into shares when settled.
Key Details
- Transaction date: May 14, 2026; Filing date: May 18, 2026 (filed within the standard two-business-day Form 4 window).
- Transaction type/code: Grant/Award (A); reported price: $0.00.
- Shares/units granted: 8,741 RSUs (1 RSU = 1 share upon settlement).
- Shares owned after transaction: Not specified in this filing.
- Footnote: RSUs vest on the earlier of May 14, 2027 or the Issuer's 2027 Annual Meeting, subject to continued board service. RSUs may be settled in shares on the vesting date or earlier upon the director’s election in cases of service termination, death/disability, or a change in control.
Context
This is a compensation-related equity award for board service, not an open-market purchase or sale. RSUs are contingent and do not represent immediately tradable shares until settled upon vesting or other qualifying events. Such grants are routine for directors and reflect compensation rather than a direct trading signal.
Insider Transaction Report
- Award
Common Stock
[F1]2026-05-14+8,741→ 28,323 total
Footnotes (1)
- [F1]Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.